Search research articles
Contact Us
Filters
Showing results (31-40 of 62) with videos related to
Page
of 7
Sort By:
The Lancet. Oncology
|
November 9, 2002
Genetic testing for melanoma
Richard Kefford, Julia Newton Bishop, Margaret Tucker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, et al.
Cancer
|
March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
Allison Ackerman, Oliver Klein, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2016
Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study
Peter Fox, Rosemary L Balleine, Clara Lee, et al.
The Lancet. Oncology
|
February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
Keith T Flaherty, Michael Hennig, Sandra J Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Axel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma
Steven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Targeted Oncology
|
November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 62) with videos related to
Sort By:
Page
of 7
The Lancet. Oncology
|
November 9, 2002
Genetic testing for melanoma
Richard Kefford, Julia Newton Bishop, Margaret Tucker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, et al.
Cancer
|
March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
Allison Ackerman, Oliver Klein, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2016
Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study
Peter Fox, Rosemary L Balleine, Clara Lee, et al.
The Lancet. Oncology
|
February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
Keith T Flaherty, Michael Hennig, Sandra J Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Axel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma
Steven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Targeted Oncology
|
November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Page
of 7